Soleno Therapeutics, Inc. (SLNO) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
SLNO Revenue Growth
SLNO Revenue Analysis (2014–2025)
As of May 8, 2026, Soleno Therapeutics, Inc. (SLNO) generated trailing twelve-month (TTM) revenue of $190.4 million. The most recent quarter (Q4 2025) recorded $91.7 million in revenue, up 38.9% sequentially.
Looking at the longer-term picture, SLNO's historical revenue data shows various trends over time. The company achieved its highest annual revenue of $190.4 million in 2025, representing a new all-time high.
When compared to Healthcare sector peers including RARE (+13.3% YoY), ACAD (+9.9% YoY), and RYTM (+58.7% YoY). Compare SLNO vs RARE →
SLNO Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| SLNOCurrent | $190M | - | - | 7.9% | |
 RARE | $673M | +13.3% | +19.9% | -79.5% | |
 ACAD | $1.1B | +9.9% | +19.4% | 9.8% | |
 RYTM | $190M | +58.7% | - | -101.2% | |
 MDGL | $958M | +256.8% | - | -31.3% | |
 PTCT | $1.7B | -53.3% | +35.4% | 49.5% |
SLNO Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $190.4M | - | $187.7M | 98.6% | $14.9M | 7.9% |
| 2024 | $0 | - | $0 | - | $-187,671,000 | - |
| 2023 | $0 | - | $0 | - | $-41,384,000 | - |
| 2022 | $0 | - | $0 | - | $-24,397,000 | - |
| 2021 | $0 | - | $0 | - | $-31,528,000 | - |
| 2020 | $0 | - | $-2,194,000 | - | $-31,949,000 | - |
| 2019 | $0 | - | $-2,297,000 | - | $-23,197,000 | - |
| 2018 | $0 | +100.0% | $-1,919,000 | - | $-14,301,000 | - |
| 2017 | $-1,553,002,000 | -107145.4% | $-1,554,613,000 | 100.1% | $-12,171,315 | 0.8% |
| 2016 | $1.5M | +274.3% | $-58,518 | -4.0% | $-13,610,115 | -938.1% |
See SLNO's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs SLNO Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare SLNO vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonSLNO — Frequently Asked Questions
Quick answers to the most common questions about buying SLNO stock.
Is SLNO's revenue growth accelerating or slowing?
SLNO TTM revenue: $190M. YoY growth: N/A. 5-year CAGR: N/A.
What is SLNO's long-term revenue growth rate?
Soleno Therapeutics, Inc.'s 5-year revenue CAGR of N/A reflects the variable expansion pattern. Current YoY growth of N/A is near this long-term average.
How is SLNO's revenue distributed by segment?
SLNO reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.